| Chen, Xiaozhong |
NCT04061278: A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 246 | RoW | 4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, 3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Nasopharyngeal Carcinoma, Neoadjuvant Chemotherapy | 06/22 | 12/22 | | |
IRCNPC, NCT03015727: Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 440 | RoW | Docetaxel, DOC, Cisplatin, DDP, IMRT/TOMO, Chemotherapy, concurrent chemotherapy | Zhejiang Cancer Hospital, Zhejiang Provincial People's Hospital, The Central Hospital of Lishui City, Jinhua Central Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Eastern Hospital, People's Hospital of Quzhou | Locally Advanced Nasopharyngeal Carcinoma | 12/22 | 12/24 | | |
NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 278 | Canada, US, RoW | Penpulimab, cisplatin, gemcitabine, placebo | Akeso | Nasopharyngeal Carcinoma | 02/25 | 09/26 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 212 | RoW | PD-1 blocking antibody, JS001, GP, IMRT | Sun Yat-sen University | Recurrent Nasopharyngeal Carcinoma | 12/25 | 12/28 | | |
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial |
|
|
| Recruiting | 3 | 212 | RoW | Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
NCT03678649: A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC |
|
|
| Recruiting | 2 | 180 | RoW | Capecitabine | Zhejiang Cancer Hospital | Head and Neck Neoplasms | 12/20 | 12/23 | | |
NCT03904225: Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis |
|
|
| Recruiting | 2 | 220 | RoW | Tegafur-Gimeracil-Oteracil | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 12/22 | 12/22 | | |
NCT05232552: Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 37 | RoW | Anlotinib hydrochloride, induction chemotherapy, IC, concurrent chemoradiation, CCRT | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 12/22 | 12/24 | | |
NCT04736810: A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma |
|
|
| Completed | 2 | 28 | RoW | AK105, Cisplatin, Gemcitabine, Anlotinib hydrochloride | Akeso, Akeso Tiancheng, Inc | Nasopharyngeal Carcinoma | 06/22 | 12/23 | | |
NCT06055816: Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Endostar and Envafolimab | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 09/24 | 06/28 | | |
NCT05813626: Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 89 | RoW | Toripalimab | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 10/24 | 10/27 | | |
NCT05024019: Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery |
|
|
| Not yet recruiting | 2 | 95 | RoW | Nimotuzumab | Eye & ENT Hospital of Fudan University | Head and Neck Squamous Cell Carcinoma | 08/25 | 08/25 | | |
| Recruiting | 1/2 | 114 | RoW | AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil | Akeso | Advanced Malignant Tumors | 02/23 | 02/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT03657017: PET/MR in Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 150 | RoW | PET/MR | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma, PET/MR | 06/22 | 12/25 | | |
NCT05126160: Immune Score Based Radiomics in Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 494 | RoW | Immune Score Based Radiomics | Zhejiang Cancer Hospital, Renmin Hospital of Wuhan University, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Ningbo No. 1 Hospital | Nasopharyngeal Carcinoma | 10/22 | 12/27 | | |
